Skip to main navigation

Skip to Content

News
Contact Us
Investors
- Overview
- Events and Presentations
- SEC Filings
- Stock Information
- Corporate Governance
- Investor FAQs
- Email Alerts

Home
About
- About Cullinan
- Leadership
- Partnerships
Research
- R&D
- Programs
- Pipeline
For Patients
- Patient Programs
- Clinical Trials
Working at Cullinan
- Our People
- Careers

News Releases

Year

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

November 14, 2024

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

November 7, 2024

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

November 5, 2024

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

November 4, 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

October 16, 2024

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

September 17, 2024

Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

September 16, 2024

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

September 14, 2024

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

August 28, 2024

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

August 8, 2024

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 21

Connect With Us

Follow Us

Site - Social

Site - Footer

Connect With Us
Terms of Use
Privacy Notice
Cookie Notice
Accessibility Policy

© COPYRIGHT 2024 Cullinan Therapeutics, Inc. | ALL RIGHTS RESERVED